Status:
COMPLETED
Prevention of Hepatitis B Virus Mother-to-child Transmission by Serovaccination.
Lead Sponsor:
Hopital Lariboisière
Conditions:
Hepatitis B
Eligibility:
FEMALE
18-45 years
Brief Summary
The prevalence of HBsAg carriage in pregnant women varies in France, according to the native country, with highest rates in those originating from sub-Saharan Africa and Asia (5 to 8 % in Parisian are...
Detailed Description
This monocentre, observational study will include pregnant women whom HBV-DNA is \> 105 IU/mL. HBV MTCT rates will be evaluated, according to the level of HBV-DNA in the women during the last three mo...
Eligibility Criteria
Inclusion
- Pregnant woman
- whom HBs Ag +
- whom HBV-DNA \>105 IU/mL
Exclusion
- Women who have to be treated for HBV hepatitis, (AST/ALT \>2 ULN without any explanation, liver biopsy performed before pregnancy showing hepatitis requiring initiation of treatment)
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01810835
Start Date
November 1 2011
End Date
November 1 2013
Last Update
December 6 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Lariboisiere
Paris, France, 75475
2
Paris, France